table of content
1 Opioid Induced Constipation (OIC) Drugs Market Overview
1.1 Product Overview and Scope of Opioid Induced Constipation (OIC) Drugs
1.2 Opioid Induced Constipation (OIC) Drugs Segment by Type
1.2.1 Global Opioid Induced Constipation (OIC) Drugs Sales Growth Rate Comparison by Type (2023-2030)
1.2.2 Lubiprostone
1.2.3 Methyl Naltrexone Bromide
1.2.4 Naldemedine
1.2.5 Alvimopan
1.2.6 Others
1.3 Opioid Induced Constipation (OIC) Drugs Segment by Application
1.3.1 Global Opioid Induced Constipation (OIC) Drugs Sales Comparison by Application: (2023-2030)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global Opioid Induced Constipation (OIC) Drugs Market Size Estimates and Forecasts
1.4.1 Global Opioid Induced Constipation (OIC) Drugs Revenue 2017-2030
1.4.2 Global Opioid Induced Constipation (OIC) Drugs Sales 2017-2030
1.4.3 Opioid Induced Constipation (OIC) Drugs Market Size by Region: 2017 Versus 2021 Versus 2030
2 Opioid Induced Constipation (OIC) Drugs Market Competition by Manufacturers
2.1 Global Opioid Induced Constipation (OIC) Drugs Sales Market Share by Manufacturers (2017-2023)
2.2 Global Opioid Induced Constipation (OIC) Drugs Revenue Market Share by Manufacturers (2017-2023)
2.3 Global Opioid Induced Constipation (OIC) Drugs Average Price by Manufacturers (2017-2023)
2.4 Manufacturers Opioid Induced Constipation (OIC) Drugs Manufacturing Sites, Area Served, Product Type
2.5 Opioid Induced Constipation (OIC) Drugs Market Competitive Situation and Trends
2.5.1 Opioid Induced Constipation (OIC) Drugs Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Opioid Induced Constipation (OIC) Drugs Players Market Share by Revenue
2.5.3 Global Opioid Induced Constipation (OIC) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Opioid Induced Constipation (OIC) Drugs Retrospective Market Scenario by Region
3.1 Global Opioid Induced Constipation (OIC) Drugs Retrospective Market Scenario in Sales by Region: 2017-2023
3.2 Global Opioid Induced Constipation (OIC) Drugs Retrospective Market Scenario in Revenue by Region: 2017-2023
3.3 North America Opioid Induced Constipation (OIC) Drugs Market Facts & Figures by Country
3.3.1 North America Opioid Induced Constipation (OIC) Drugs Sales by Country
3.3.2 North America Opioid Induced Constipation (OIC) Drugs Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Opioid Induced Constipation (OIC) Drugs Market Facts & Figures by Country
3.4.1 Europe Opioid Induced Constipation (OIC) Drugs Sales by Country
3.4.2 Europe Opioid Induced Constipation (OIC) Drugs Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Opioid Induced Constipation (OIC) Drugs Market Facts & Figures by Region
3.5.1 Asia Pacific Opioid Induced Constipation (OIC) Drugs Sales by Region
3.5.2 Asia Pacific Opioid Induced Constipation (OIC) Drugs Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Opioid Induced Constipation (OIC) Drugs Market Facts & Figures by Country
3.6.1 Latin America Opioid Induced Constipation (OIC) Drugs Sales by Country
3.6.2 Latin America Opioid Induced Constipation (OIC) Drugs Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Opioid Induced Constipation (OIC) Drugs Market Facts & Figures by Country
3.7.1 Middle East and Africa Opioid Induced Constipation (OIC) Drugs Sales by Country
3.7.2 Middle East and Africa Opioid Induced Constipation (OIC) Drugs Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Opioid Induced Constipation (OIC) Drugs Historic Market Analysis by Type
4.1 Global Opioid Induced Constipation (OIC) Drugs Sales Market Share by Type (2017-2023)
4.2 Global Opioid Induced Constipation (OIC) Drugs Revenue Market Share by Type (2017-2023)
4.3 Global Opioid Induced Constipation (OIC) Drugs Price by Type (2017-2023)
5 Global Opioid Induced Constipation (OIC) Drugs Historic Market Analysis by Application
5.1 Global Opioid Induced Constipation (OIC) Drugs Sales Market Share by Application (2017-2023)
5.2 Global Opioid Induced Constipation (OIC) Drugs Revenue Market Share by Application (2017-2023)
5.3 Global Opioid Induced Constipation (OIC) Drugs Price by Application (2017-2023)
6 Key Companies Profiled
6.1 Ironwood Pharmaceuticals Inc
6.1.1 Ironwood Pharmaceuticals Inc Corporation Information
6.1.2 Ironwood Pharmaceuticals Inc Description and Business Overview
6.1.3 Ironwood Pharmaceuticals Inc Opioid Induced Constipation (OIC) Drugs Sales, Revenue and Gross Margin (2017-2023)
6.1.4 Ironwood Pharmaceuticals Inc Opioid Induced Constipation (OIC) Drugs Product Portfolio
6.1.5 Ironwood Pharmaceuticals Inc Recent Developments/Updates
6.2 Daiichi Sankyo Co Ltd
6.2.1 Daiichi Sankyo Co Ltd Corporation Information
6.2.2 Daiichi Sankyo Co Ltd Description and Business Overview
6.2.3 Daiichi Sankyo Co Ltd Opioid Induced Constipation (OIC) Drugs Sales, Revenue and Gross Margin (2017-2023)
6.2.4 Daiichi Sankyo Co Ltd Opioid Induced Constipation (OIC) Drugs Product Portfolio
6.2.5 Daiichi Sankyo Co Ltd Recent Developments/Updates
6.3 Pfizer
6.3.1 Pfizer Corporation Information
6.3.2 Pfizer Description and Business Overview
6.3.3 Pfizer Opioid Induced Constipation (OIC) Drugs Sales, Revenue and Gross Margin (2017-2023)
6.3.4 Pfizer Opioid Induced Constipation (OIC) Drugs Product Portfolio
6.3.5 Pfizer Recent Developments/Updates
6.4 Progenics Pharmaceuticals Inc
6.4.1 Progenics Pharmaceuticals Inc Corporation Information
6.4.2 Progenics Pharmaceuticals Inc Description and Business Overview
6.4.3 Progenics Pharmaceuticals Inc Opioid Induced Constipation (OIC) Drugs Sales, Revenue and Gross Margin (2017-2023)
6.4.4 Progenics Pharmaceuticals Inc Opioid Induced Constipation (OIC) Drugs Product Portfolio
6.4.5 Progenics Pharmaceuticals Inc Recent Developments/Updates
6.5 Shionogi & Co., Ltd
6.5.1 Shionogi & Co., Ltd Corporation Information
6.5.2 Shionogi & Co., Ltd Description and Business Overview
6.5.3 Shionogi & Co., Ltd Opioid Induced Constipation (OIC) Drugs Sales, Revenue and Gross Margin (2017-2023)
6.5.4 Shionogi & Co., Ltd Opioid Induced Constipation (OIC) Drugs Product Portfolio
6.5.5 Shionogi & Co., Ltd Recent Developments/Updates
6.6 Allergan Plc
6.6.1 Allergan Plc Corporation Information
6.6.2 Allergan Plc Description and Business Overview
6.6.3 Allergan Plc Opioid Induced Constipation (OIC) Drugs Sales, Revenue and Gross Margin (2017-2023)
6.6.4 Allergan Plc Opioid Induced Constipation (OIC) Drugs Product Portfolio
6.6.5 Allergan Plc Recent Developments/Updates
6.7 Nektar Therapeutics
6.6.1 Nektar Therapeutics Corporation Information
6.6.2 Nektar Therapeutics Description and Business Overview
6.6.3 Nektar Therapeutics Opioid Induced Constipation (OIC) Drugs Sales, Revenue and Gross Margin (2017-2023)
6.4.4 Nektar Therapeutics Opioid Induced Constipation (OIC) Drugs Product Portfolio
6.7.5 Nektar Therapeutics Recent Developments/Updates
6.8 Purdue Pharma
6.8.1 Purdue Pharma Corporation Information
6.8.2 Purdue Pharma Description and Business Overview
6.8.3 Purdue Pharma Opioid Induced Constipation (OIC) Drugs Sales, Revenue and Gross Margin (2017-2023)
6.8.4 Purdue Pharma Opioid Induced Constipation (OIC) Drugs Product Portfolio
6.8.5 Purdue Pharma Recent Developments/Updates
6.9 S.L.A. Pharma AG
6.9.1 S.L.A. Pharma AG Corporation Information
6.9.2 S.L.A. Pharma AG Description and Business Overview
6.9.3 S.L.A. Pharma AG Opioid Induced Constipation (OIC) Drugs Sales, Revenue and Gross Margin (2017-2023)
6.9.4 S.L.A. Pharma AG Opioid Induced Constipation (OIC) Drugs Product Portfolio
6.9.5 S.L.A. Pharma AG Recent Developments/Updates
6.10 Mundipharma International Limited
6.10.1 Mundipharma International Limited Corporation Information
6.10.2 Mundipharma International Limited Description and Business Overview
6.10.3 Mundipharma International Limited Opioid Induced Constipation (OIC) Drugs Sales, Revenue and Gross Margin (2017-2023)
6.10.4 Mundipharma International Limited Opioid Induced Constipation (OIC) Drugs Product Portfolio
6.10.5 Mundipharma International Limited Recent Developments/Updates
6.11 Ono Pharmaceutical Co., Ltd
6.11.1 Ono Pharmaceutical Co., Ltd Corporation Information
6.11.2 Ono Pharmaceutical Co., Ltd Opioid Induced Constipation (OIC) Drugs Description and Business Overview
6.11.3 Ono Pharmaceutical Co., Ltd Opioid Induced Constipation (OIC) Drugs Sales, Revenue and Gross Margin (2017-2023)
6.11.4 Ono Pharmaceutical Co., Ltd Opioid Induced Constipation (OIC) Drugs Product Portfolio
6.11.5 Ono Pharmaceutical Co., Ltd Recent Developments/Updates
6.12 Takeda Pharmaceutical Company Limited
6.12.1 Takeda Pharmaceutical Company Limited Corporation Information
6.12.2 Takeda Pharmaceutical Company Limited Opioid Induced Constipation (OIC) Drugs Description and Business Overview
6.12.3 Takeda Pharmaceutical Company Limited Opioid Induced Constipation (OIC) Drugs Sales, Revenue and Gross Margin (2017-2023)
6.12.4 Takeda Pharmaceutical Company Limited Opioid Induced Constipation (OIC) Drugs Product Portfolio
6.12.5 Takeda Pharmaceutical Company Limited Recent Developments/Updates
6.13 Theravance Biopharma Inc
6.13.1 Theravance Biopharma Inc Corporation Information
6.13.2 Theravance Biopharma Inc Opioid Induced Constipation (OIC) Drugs Description and Business Overview
6.13.3 Theravance Biopharma Inc Opioid Induced Constipation (OIC) Drugs Sales, Revenue and Gross Margin (2017-2023)
6.13.4 Theravance Biopharma Inc Opioid Induced Constipation (OIC) Drugs Product Portfolio
6.13.5 Theravance Biopharma Inc Recent Developments/Updates
6.14 Bausch Health
6.14.1 Bausch Health Corporation Information
6.14.2 Bausch Health Opioid Induced Constipation (OIC) Drugs Description and Business Overview
6.14.3 Bausch Health Opioid Induced Constipation (OIC) Drugs Sales, Revenue and Gross Margin (2017-2023)
6.14.4 Bausch Health Opioid Induced Constipation (OIC) Drugs Product Portfolio
6.14.5 Bausch Health Recent Developments/Updates
6.15 Cosmo Pharmaceuticals SA
6.15.1 Cosmo Pharmaceuticals SA Corporation Information
6.15.2 Cosmo Pharmaceuticals SA Opioid Induced Constipation (OIC) Drugs Description and Business Overview
6.15.3 Cosmo Pharmaceuticals SA Opioid Induced Constipation (OIC) Drugs Sales, Revenue and Gross Margin (2017-2023)
6.15.4 Cosmo Pharmaceuticals SA Opioid Induced Constipation (OIC) Drugs Product Portfolio
6.15.5 Cosmo Pharmaceuticals SA Recent Developments/Updates
6.16 Daewoong Pharmaceutical
6.16.1 Daewoong Pharmaceutical Corporation Information
6.16.2 Daewoong Pharmaceutical Opioid Induced Constipation (OIC) Drugs Description and Business Overview
6.16.3 Daewoong Pharmaceutical Opioid Induced Constipation (OIC) Drugs Sales, Revenue and Gross Margin (2017-2023)
6.16.4 Daewoong Pharmaceutical Opioid Induced Constipation (OIC) Drugs Product Portfolio
6.16.5 Daewoong Pharmaceutical Recent Developments/Updates
6.17 C.B. Fleet Company
6.17.1 C.B. Fleet Company Corporation Information
6.17.2 C.B. Fleet Company Opioid Induced Constipation (OIC) Drugs Description and Business Overview
6.17.3 C.B. Fleet Company Opioid Induced Constipation (OIC) Drugs Sales, Revenue and Gross Margin (2017-2023)
6.17.4 C.B. Fleet Company Opioid Induced Constipation (OIC) Drugs Product Portfolio
6.17.5 C.B. Fleet Company Recent Developments/Updates
6.18 Sucampo Pharmaceuticals
6.18.1 Sucampo Pharmaceuticals Corporation Information
6.18.2 Sucampo Pharmaceuticals Opioid Induced Constipation (OIC) Drugs Description and Business Overview
6.18.3 Sucampo Pharmaceuticals Opioid Induced Constipation (OIC) Drugs Sales, Revenue and Gross Margin (2017-2023)
6.18.4 Sucampo Pharmaceuticals Opioid Induced Constipation (OIC) Drugs Product Portfolio
6.18.5 Sucampo Pharmaceuticals Recent Developments/Updates
7 Opioid Induced Constipation (OIC) Drugs Manufacturing Cost Analysis
7.1 Opioid Induced Constipation (OIC) Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Opioid Induced Constipation (OIC) Drugs
7.4 Opioid Induced Constipation (OIC) Drugs Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Opioid Induced Constipation (OIC) Drugs Distributors List
8.3 Opioid Induced Constipation (OIC) Drugs Customers
9 Opioid Induced Constipation (OIC) Drugs Market Dynamics
9.1 Opioid Induced Constipation (OIC) Drugs Industry Trends
9.2 Opioid Induced Constipation (OIC) Drugs Market Drivers
9.3 Opioid Induced Constipation (OIC) Drugs Market Challenges
9.4 Opioid Induced Constipation (OIC) Drugs Market Restraints
10 Global Market Forecast
10.1 Opioid Induced Constipation (OIC) Drugs Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Opioid Induced Constipation (OIC) Drugs by Type (2023-2030)
10.1.2 Global Forecasted Revenue of Opioid Induced Constipation (OIC) Drugs by Type (2023-2030)
10.2 Opioid Induced Constipation (OIC) Drugs Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Opioid Induced Constipation (OIC) Drugs by Application (2023-2030)
10.2.2 Global Forecasted Revenue of Opioid Induced Constipation (OIC) Drugs by Application (2023-2030)
10.3 Opioid Induced Constipation (OIC) Drugs Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Opioid Induced Constipation (OIC) Drugs by Region (2023-2030)
10.3.2 Global Forecasted Revenue of Opioid Induced Constipation (OIC) Drugs by Region (2023-2030)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
